Streetbeat News

Products Services

VBIV

VBI Vaccines has expanded its collaboration with the Canadian government, directing the remaining C$28M of the initially committed C$56M towards the development of its MLE Platform.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:09 pm

VBIV

VBI Vaccines has announced an expansion of its strategic partnership with the Canadian government, directing the remaining CAD$28M of the original CAD$56M award towards the continued development of its proprietary technology platforms.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:08 pm

CWAN

Clearwater Analytics is acquiring risk and performance analytics solutions from Wilshire Advisors for approximately $40 million. The acquisition includes Wilshire Axiom, Wilshire Atlas, Wilshire Abacus, and Wilshire iQComposite, which will be integrated into Clearwater's platform, enhancing its offerings in fixed income and equity analytics, performance measurement, accounting, and GIPS compliance support. This move is expected to add about $7 million in annualized revenue to Clearwater.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:08 pm

MSFT

Microsoft is currently testing a new AI-powered chatbot for Xbox, aimed at automating support tasks. This development could enhance user experience and efficiency in handling support queries.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:06 pm

MIRA

Mira Pharmaceuticals shared updates on its preclinical studies for Ketamir-2, expressing optimism that the results will allow the company to file a New Drug Application (NDA) with the FDA by the end of this year.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:04 pm

HUM

IRON

SYRS

The article highlights the top 3 oversold health care stocks, identified by their low RSI values, suggesting potential investment opportunities. Syros Pharmaceuticals, Disc Medicine, and Humana Inc. are mentioned as having RSI values below 30, indicating they are oversold. Syros Pharmaceuticals reported weaker-than-expected Q4 results but is optimistic about future data. Disc Medicine reported topline results from a Phase 2 study, causing a significant stock drop. Humana was initiated with a Market Perform rating by Raymond James, experiencing a stock decline over six months.

Portfolio Pulse from Avi Kapoor

April 02, 2024 | 12:02 pm

PRFX

PainReform has enrolled over 200 patients in its clinical trials out of an anticipated 400 across eight sites in the U.S., as reported exclusively to Benzinga.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:00 pm

JAZZ

Jazz Pharmaceuticals has completed the biologics license application for Zanidatamab, aimed at treating previously treated HER2-positive metastatic biliary tract cancer. This marks a significant step in providing a new treatment option for this cancer type.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:00 pm

PRFX

PainReform, as reported by Benzinga, has confirmed that it is on schedule to announce its top-line data by mid-2024. This announcement is crucial for investors as it indicates the company's progress on its developments and potential future growth.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:00 pm

PRFX

PainReform has reached 50% enrollment in the second part of its Phase III clinical trial of PRF-110 for bunionectomy, as exclusively reported to Benzinga.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:00 pm